The trial is randomized and double-blind, meaning participants are assigned by chance to receive either the probiotic or a placebo, and neither families nor doctors know which one is given. After completing the standard course of antibiotic treatment, the child takes the study liquid for about 30 days at home. Over the following six months, follow‑up visits and calls record any new infections, hospital stays, extra antibiotic use, and symptoms such as stomach pain or diarrhea, and a laboratory culture test may be used to confirm any new infection.

Participants who have finished first‑line chemotherapy and are either in complete remission (no detectable cancer) or have stable disease are randomly assigned to one of the two groups. They take the study medication daily for a defined period while regular check‑ups, scans, and questionnaires about quality of life are performed. The study follows each participant for several years to record any return of cancer, new health problems, or death, and the information is used to compare the two treatment approaches.

The purpose of the study is to learn about the safety of BIIB080 and whether it can improve symptoms in participants. Participants will receive the treatment through an injection into the spinal fluid, a method known as intrathecal use. The study will last for a period of 76 weeks, during which participants will be monitored for changes in their cognitive abilities and overall health. The study aims to understand how different doses of the treatment affect the symptoms of Alzheimer’s disease.

Throughout the study, participants will undergo various assessments to track their progress. These assessments include tests to measure memory and thinking skills, as well as monitoring for any side effects or adverse events. The study is designed to provide valuable information on the potential benefits and safety of BIIB080 for individuals with early stages of Alzheimer’s disease.

The purpose of the study is to see whether oral semaglutide can help slow worsening of memory, thinking, and daily function in people with early Alzheimer’s disease, and to check its safety. The study is randomised, which means the treatment is assigned by chance, and double-blind, which means neither the participants nor the study team knows who receives semaglutide or placebo during the study. Treatment is taken by mouth over a long period, and the study follows changes over time.

Participants take the study tablets regularly and are seen at planned visits during the trial. These visits are used to monitor health, review how the person is doing, and record any changes in memory, daily activities, or side effects. The study compares how people do over time in the semaglutide and placebo groups.

People in the study are assigned to one of the two medicines. The treatment is given over time as intravenous infusions, which means medicine is put directly into a vein. The study is double-blind, which means the people taking part and the study doctors do not know which treatment is being given. During the study, doctors follow how the cancer changes, watch for side effects, and check how well each medicine is tolerated.

People in the study are placed into one of the treatment groups by chance. Treatment is given as intravenous infusion, which means medicine is delivered slowly through a vein. The study is planned to follow people over time while they receive treatment and after treatment ends to see how they do. The trial also watches for side effects, including cytokine release syndrome, a strong immune reaction, and ICANS, which is a group of brain and nerve symptoms that can happen with some immune treatments.

Obrixtamig is also known by the code name BI 764532. It is a type of treatment called a T cell engager, which is designed to help the immune system find and attack cancer cells that have DLL3 on their surface. The study is for previously untreated cancer that is DLL3-positive, meaning the cancer cells have this marker.

In the study, people are randomly assigned to receive either the new treatment combination or the standard treatment combination. The medicines are given as intravenous infusion, which means they are delivered slowly through a vein. Treatment is given in cycles over time, with regular visits for infusions and checks by the study team. The study will look at how long people live and will also follow symptoms and side effects, including breathing problems, chest pain, cough, and treatment-related reactions such as CRS and ICANS. CRS, or cytokine release syndrome, is a strong immune reaction that can cause fever and other symptoms. ICANS, or immune effector cell-associated neurotoxicity syndrome, is a brain and nerve problem that can affect thinking, speech, or alertness.

The study has more than one part. In one part, EIK1005 is given by itself. In another part, EIK1005 is given with pembrolizumab. Participants may take the study tablet on a regular schedule and receive pembrolizumab through a vein during clinic visits. During the study, doctors watch for side effects and other health changes, and treatment may be adjusted as needed. The study also includes people with tumors that are MSI-H or dMMR, which are tumor features linked to problems in how cancer cells repair damage in their genetic material.

EIK1005 is also called a Werner helicase inhibitor. A helicase is a protein that helps cells handle and copy genetic material, and this medicine is designed to block that protein. The trial is planned to continue over several years while safety and dose information are collected.

The main goal is to assess the long‑term safety and tolerability of the medicine, meaning researchers will watch for any side effects or problems over an extended period. After the initial treatment period, participants will continue to attend regular visits where doctors will ask about health changes, perform a simple nasal examination, and may take a small blood sample to check drug levels. The study also records whether participants need additional treatments such as a short course of a systemic corticosteroid (a pill that reduces inflammation throughout the body) or sinus surgery.

The study follows people who receive the study drug and looks at how the treatment is tolerated over time. Some extra testing of tumor samples or blood samples may be done to look for markers in the cancer, which are small signs that can help explain how the cancer is behaving. These tests are optional and are used for research only.

The purpose of this study is to see whether Tozorakimab can reduce the number of times COPD symptoms suddenly get worse, which are called exacerbations. These exacerbations are episodes when breathing problems become more severe than usual and may require additional treatment or even hospitalization. The study will compare two different amounts of Tozorakimab given as an injection under the skin to placebo, which will be added to the standard medications that participants are already taking for their COPD.

The study will last for about 52 weeks. During this time, participants will receive regular injections of either Tozorakimab or placebo, and doctors will monitor how often their COPD symptoms worsen and how severe these episodes are. The study focuses on people who have had at least two moderate episodes or one severe episode of worsening COPD symptoms in the past year, who are former smokers, and who continue to have symptoms despite using their regular COPD medications.

The study is designed as a randomized, double-blind trial where participants will receive either NBI-1065845 or a placebo alongside their current antidepressant medication. The treatment period will last for approximately 56 days (8 weeks), during which the medication’s effects on depression symptoms will be monitored.

Participants in this study must have recurrent MDD (occurring multiple times) that is moderate or severe, or persistent depressive disorder (a long-term form of depression). They must already be taking oral antidepressant treatments but experiencing an inadequate response to these medications despite proper dosing and duration.

Participants in the study will be randomly assigned to receive either BHV-7000 or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for about eight weeks, during which participants will take the medication or placebo daily. Researchers will monitor the participants to see if there is a reduction in the number of seizures they experience. The goal is to find out if BHV-7000 can help reduce seizures by at least 50% in those taking the medication compared to those taking the placebo.

Throughout the study, the safety and tolerability of BHV-7000 will be closely observed. This means researchers will keep track of any side effects or adverse reactions participants might experience. The study aims to provide valuable information on whether BHV-7000 can be a beneficial treatment option for people with Refractory Focal Onset Epilepsy, potentially offering a new way to manage this challenging condition.

The purpose of the study is to evaluate the effectiveness and safety of Upadacitinib, which is a type of medication known as a Janus Kinase (Jak) 1 Inhibitor. This medication is taken orally in the form of a modified-release tablet, which means it is designed to release the active ingredient slowly over time. Participants in the study will receive either Upadacitinib or a placebo, which is a substance with no active medication, to compare the outcomes.

Throughout the study, participants will be monitored to see how their eczema symptoms change over time. The study will last for several months, and participants will have regular check-ups to assess their skin condition and overall health. The goal is to determine if Upadacitinib can significantly improve the symptoms of eczema and enhance the quality of life for those affected by this condition.

Participants in the study will receive medications through an intravenous infusion, which is a method of delivering medicine directly into a vein. The study involves comparing different combinations of drugs to see how they affect progression-free survival, a term used to describe the length of time during and after treatment that a person lives with the disease without it getting worse. Other factors being observed include overall survival and the quality of life, which tracks how well a person can perform daily activities and their general well-being during the study.

The main purpose of this study is to compare how long people live when treated with the investigational medicine compared to docetaxel. The study will look at this in all people whose tumors have PD-L1 levels of at least one percent, and also specifically in those whose tumors have PD-L1 levels of fifty percent or higher. People taking part will be randomly assigned to receive either the investigational medicine or docetaxel. The study will also look at other things like how well the tumors respond to treatment, how long any response lasts, and what side effects occur with each treatment.

During the study, participants will receive their assigned treatment for up to sixty months. Those receiving the investigational medicine will get it at a dose based on their body weight, while those receiving docetaxel will get it at a dose based on their body surface area. The study team will regularly check how the cancer is responding to treatment and monitor for any side effects. Participants will also be asked about their quality of life and any symptoms they are experiencing. Blood samples will be taken from those receiving the investigational medicine to measure drug levels in the body and to check for immune responses to the medicine. Tumor tissue samples will also be collected for testing to help understand how the treatments work.

The purpose of the study is to find out if adding Saruparib to the standard treatment of radiotherapy and androgen deprivation therapy can help men with this type of prostate cancer live longer without the cancer spreading to distant parts of the body compared to placebo. The study will measure how long participants remain free of distant spread of cancer, which is called metastases-free survival, and will also look at overall survival and other measures of how well the treatment works. During the study, participants will receive the study medication in tablet form taken by mouth, and they will need to have various scans including computed tomography or magnetic resonance imaging, bone scans, and prostate-specific membrane antigen-positron emission tomography scans to check for any signs of cancer spread.

Participants will be randomly assigned to receive either the active study medication or placebo in addition to their standard treatment, and neither the participants nor their doctors will know which treatment they are receiving during the study. The study requires tissue samples from the prostate cancer to confirm the presence of the BRCA gene mutation before enrollment. Throughout the study, participants will be monitored for how the treatment affects their cancer, their overall health, and their quality of life through questionnaires about symptoms and daily functioning. Blood samples will also be collected to measure the levels of the study medication in the body and to understand how it works.

The purpose of this study is to evaluate the long-term safety and how well GSK4527226 works in people with early Alzheimer’s Disease. This is an extension study, which means it follows people who have already completed a previous study with the same medication. The study will look at any side effects that occur and will pay special attention to certain brain-related imaging findings that can sometimes happen with this type of treatment. These findings are monitored using brain scans to ensure participant safety throughout the study.

Participants will continue receiving GSK4527226 for up to 104 weeks, which is about two years. During this time, they will attend regular clinic visits where doctors will check their health and monitor for any unwanted effects. The study will also measure changes in memory, thinking abilities, and daily functioning using various assessments and questionnaires. A study partner, such as a family member or close friend who spends regular time with the participant, will need to attend some visits to provide information about how the participant is managing daily activities. All participants in this study will receive the active medication, as this is not a comparison study with placebo.

The purpose of this study is to find out if ziltivekimab works better than placebo in reducing the risk of death from heart and blood vessel problems and preventing heart failure events such as hospital stays or urgent visits for worsening heart failure. The study will also look at other health outcomes including the combined risk of death from heart problems, heart attacks, and strokes, as well as how the treatment affects kidney function, quality of life, and inflammation levels in the body. Quality of life will be measured using questionnaires that ask about symptoms and daily activities.

During the study, participants will receive monthly injections for up to 48 months. The study will track various health events including hospitalizations for heart failure, deaths, heart attacks, strokes, and changes in heart and kidney function. Blood tests will be done to measure inflammation markers like hs-CRP and heart stress markers like NT-proBNP. Heart function will be checked using echocardiography, which is an ultrasound test that creates pictures of the heart. The study will continue until enough information has been collected to determine whether ziltivekimab is effective in helping people with this type of heart failure and inflammation.

The study will involve people with mild to moderate Alzheimer’s Disease, who will receive either the study medications or placebo for 24 weeks. The medications are being tested to see if they can help improve cognitive function (thinking abilities) and daily functioning in people with Alzheimer’s Disease.

During the study, participants will take the medication daily and attend regular check-ups where their mental abilities and overall condition will be assessed. The study will track any changes in participants’ ability to think, perform daily activities, and their overall health status. Healthcare providers will monitor participants’ safety throughout the study period.

The study involves patients whose lung cancer has already been treated with platinum-based chemotherapy combined with immunotherapy but has since returned. Both medications in this study will be given through intravenous infusion (delivered directly into a vein). GSK5764227 will be given at doses up to 8 milligrams per kilogram of body weight, while topotecan will be given at doses up to 1.5 milligrams per square meter of body surface area.

This is an open-label study, which means both the doctors and patients will know which treatment is being given. The treatment period may last up to 24 months, during which time doctors will monitor how well the cancer responds to the treatment and track the overall survival of patients. Throughout the study, patients will have regular check-ups to monitor their health and assess how well the treatment is working.

The purpose is to determine if using both medications together works better than empagliflozin alone in preventing serious heart-related health issues in people with these three conditions. The study will particularly look at how well this combination prevents death from heart problems and reduces the need for hospital visits due to heart failure.

Participants in this study will receive treatment for about 51 months. During this time, they will take either the combination of both medicines or empagliflozin with a placebo. Their blood pressure, kidney function, and heart health will be monitored throughout the study period. The medications being tested are designed to help manage blood sugar levels and blood pressure while protecting the heart and blood vessels.

In this study, participants will receive either rinatabart sesutecan or a treatment selected by their doctor, which may include medications such as doxorubicin or paclitaxel. These medications are administered through an IV infusion, a method where medicine is delivered directly into a vein through a small tube. The study aims to determine if the new drug works better than the standard options currently available for this condition.

During the course of the study, participants will undergo regular monitoring to track how the cancer responds to the medication and to observe any side effects. The researchers will look at how long the cancer remains stable without growing and the overall survival of the participants. This process involves continuous observation over several years to collect data on how the treatments affect the health and well-being of the individuals involved.

Participants will be assigned to receive either olpasiran or a placebo through a subcutaneous injection, which means the medication is delivered into the fatty tissue just under the skin. During the study, researchers will monitor for various health events such as ischemic stroke, which is a blockage of blood flow to the brain, and cardiovascular death. The study will also track changes in the levels of lipoprotein (a) in the blood over time to see how the treatment affects this substance.

During the study, participants will be assigned to receive one of the three different options. The treatment is provided as an oral suspension, which is a liquid medicine taken by mouth. The process involves monitoring the condition of the children over a period of time to see how they respond to the different medications.

During the course of this research, participants will receive regular doses of the study drug to observe how it affects the body over an extended period. Medical professionals will monitor various aspects of health, including vital signs such as blood pressure and heart rate, as well as electrocardiogram results, which are tests that record the electrical activity of the heart. Additionally, regular blood tests will be performed to check hematology and clinical chemistry, which are used to examine the components of the blood and the chemical balance in the body.

Participants may receive several different medications. These include cetuximab, which is given through an intravenous infusion, a method of delivering medicine directly into a vein, and MK-1084, which is taken as a pill. Other medications being studied include pembrolizumab, also given by intravenous infusion. Some people may receive a combination of these new drugs, while others may receive standard treatments like carboplatin or pemetrexed.

During the study, different groups of participants will be assigned to receive different combinations of these medicines to see which ones work best. The process involves regular monitoring to see how the body reacts to the treatments and how the cancer changes over time.